Uveal Melanoma Registry

Uveal Melanoma Registry
Using outcomes research to advance disease management provides data for future research 

The Mass Eye and Ear Uveal Melanoma Registry provides an opportunity to analyze detailed demographic, clinical, and therapeutic information on more than 5,000 patients who have been treated with PBI at Mass Eye and Ear. A blood and tissue repository was added to the registry in the mid-1990s and contains samples from more than 2,500 patients with uveal melanoma. These data are
used as a resource for biomarker and genetic research and enable Mass Eye and Ear to conduct several studies on cancer susceptibility and biomarkers. These data have been analyzed to advance our understanding of uveal melanoma and to learn more about the effectiveness of treatments offered to patients.

PBI Outcomes 
Forty years of follow-up studies show that PBI has the lowest local recurrence rate of any radiation therapy, and about 95% of patients are able to keep their eyes. Most patients experience some loss of vision, which depends on the size and location of the tumor. Ten years after treatment, 30% of all patients still have vision better than 20/200. Patients with smaller tumors located further away from the optic nerve and macula can have much better visual outcomes. Ten years after PBI, about 70% of these patients have vision better than or equal to 20/200.